Indeed, a high serum sPD‐L1 level was reported to be associated with a worse prognosis than a low expression level in patients with advanced NSCLC (18.7 vs. 26.8 month, P < 0.001)26 and in patients with advanced lung cancer (13.0 vs. 20.4 months, P = 0.037).23 Here, SPDL1 is linked to lung cancer.